Financial Engines Advisors L.L.C. Makes New $222,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Financial Engines Advisors L.L.C. purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 2,401 shares of the biopharmaceutical company's stock, valued at approximately $222,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership purchased a new stake in Gilead Sciences in the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $29,000. Crews Bank & Trust purchased a new position in shares of Gilead Sciences in the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC grew its holdings in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 260 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 302,785 shares of company stock valued at $30,503,250. Insiders own 0.16% of the company's stock.

Remove Ads

Gilead Sciences Price Performance

Shares of GILD stock traded down $1.09 on Tuesday, reaching $110.96. The company's stock had a trading volume of 3,449,294 shares, compared to its average volume of 7,277,065. The company has a market capitalization of $138.18 billion, a P/E ratio of 299.89, a PEG ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The stock's 50 day simple moving average is $105.88 and its 200-day simple moving average is $95.20. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a dividend of $0.79 per share. The ex-dividend date was Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.85%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. BMO Capital Markets lifted their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Bank of America raised their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Finally, DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a research note on Thursday, February 13th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.